2-Iminobiotin
Small moleculeexperimental
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Jun 1, 2012 (NCT01626924)
Timeline
Indications
Mechanism of action
- Unspecified targetUnclear
unclear
Chemistry & pharmacology
Loading structure…
SMILES
N=C1N[C@H]2[C@H](CS[C@H]2CCCCC(=O)O)N1- Mol. weight
- 243.33 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL1233598 ↗
Also known as
- 1h-thieno(3,4-d)imidazole-4-pentanoic acid, 2-amino-3a,4,6,6a-tetrahydro-, (3as-(3aalpha,4beta,6aalpha))-
- 2-iminobiotin
- 2-iminobiotin
- 2-iminobiotin
- 2-iminobiotin
- 2-iminobiotin monohydrobromide, (3as-(3aalpha,4beta,6aalpha))-isomer
- guanidinobiotin
- guanidinobiotin
- hexahydro-2-imino-1h-thieno(3,4-d)imidazole-4-pentanoic acid
- hexahydro-2-imino-1h-thieno(3,4-d)imidazole-4-pentanoic acid
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02836340 | Phase 1/Phase 2 (Phase 2) | May 1, 2016 | University of Amsterdam |
| NCT01626924 | Phase 2 | Jun 1, 2012 | Neurophyxia B.V. |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Neurophyxia B.V. | For profit | 1 | 1 | 1 | 2012 |
| University of Amsterdam | Academic/Hospital | 1 | 1 | 1 | 2016 |
2 organizations
Page 1 / 1